Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Diametric Capital LP trimmed its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 46.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 354,010 shares of the biopharmaceutical company's stock after selling 312,829 shares during the quarter. Diametric Capital LP owned 0.18% of Esperion Therapeutics worth $779,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Cibc World Markets Corp acquired a new position in shares of Esperion Therapeutics in the fourth quarter valued at about $39,000. SJS Investment Consulting Inc. acquired a new position in shares of Esperion Therapeutics during the 4th quarter worth approximately $55,000. SLT Holdings LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $66,000. Foundations Investment Advisors LLC raised its position in shares of Esperion Therapeutics by 48.6% in the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 9,872 shares in the last quarter. Finally, J.W. Cole Advisors Inc. acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $66,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Stock Down 4.7 %

Shares of ESPR stock traded down $0.06 on Friday, reaching $1.23. The company had a trading volume of 5,281,468 shares, compared to its average volume of 5,653,087. The business's 50-day moving average is $1.70 and its 200 day moving average is $2.05. Esperion Therapeutics, Inc. has a one year low of $1.17 and a one year high of $3.94. The stock has a market capitalization of $243.35 million, a PE ratio of -1.92 and a beta of 1.04.

Remove Ads

Analyst Ratings Changes

ESPR has been the topic of a number of recent research reports. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an "overweight" rating and a $8.00 price objective on the stock. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, March 20th. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, JMP Securities restated a "market outperform" rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Esperion Therapeutics currently has an average rating of "Hold" and an average target price of $6.75.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.